Evidence map›Paper›PMID 41238650›Full record

ArticleScientific reports2025

Effects of female hormone withdrawal and ulipristal acetate on MED12 mutation positive and negative uterine leiomyomas using a xenograft model.

Shun Sato, Takahiro Sakai, Tetsuro Tamehisa, Amon Shiroshita, Hitomi Takasaki, Takuya Kajimura, Isao Tamura, Ryo Maekawa, Norihiro Sugino

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shun SatoDepartment of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Japan.
Takahiro SakaiDepartment of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Japan.
Tetsuro TamehisaDepartment of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Japan.
Amon ShiroshitaDepartment of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Japan.
Hitomi TakasakiDepartment of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Japan.
Takuya KajimuraDepartment of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Japan.
Isao TamuraDepartment of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Japan.
Ryo MaekawaDepartment of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Japan.
Norihiro SuginoDepartment of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Japan. sugino@yamaguchi-u.ac.jp.

Funding

Japan Society for the Promotion of Science JP23K27734 and JP22K19603Japan Society for the Promotion of Science JP24K12533Japan Society for the Promotion of Science JP24K12579Japan Society for the Promotion of Science,Japan JP24K12626
6 · The paper itself

Abstract

The effects of therapeutic drugs that inhibit female hormone functions on uterine leiomyomas (ULMs) vary among individuals. ULMs are classified into two subtypes with different histological compositions: MED12 mutation-positive and -negative ULMs. The present study was undertaken to investigate the tumor regression effects of female hormone withdrawal and a selective progesterone (P) receptor modulator (ulipristal acetate, UPA) in the ULM subtypes using a xenograft mouse model. Smooth muscle cells (SMCs) isolated from each ULM subtype were transplanted and treated with estrogen (E) and P for 4 weeks to form the xenograft tumor. They were then divided into four groups: continued EP treatment (E(+)P(+)), EP withdrawal (E(-)P(-)), only P withdrawal (E(+)P(-)), and EP + UPA. Tumors were harvested 8 weeks after transplantation. In both subtypes, they were reduced in size in the E(-)P(-) compared with the E(+)P(+) and further reduced in the EP + UPA. Histological analysis showed that SMCs shrank in the E(-)P(-) and disappeared in the EP + UPA. Gene ontology and pathway analyses of the differentially expressed genes of the xenograft tumors suggested that regression occurred by different mechanisms in the two subtypes. Our results also suggested, for the first time, that UPA caused SMC death by a mechanism other than progesterone receptor inhibition.

Indexed as

LeiomyomaMediator ComplexMutationNorpregnadienesUterine NeoplasmsAnimalsEstrogensFemaleHumansMiceMyocytes, Smooth MuscleProgesteroneReceptors, ProgesteroneXenograft Model Antitumor AssaysEstrogensMED12 protein, humanMediator ComplexNorpregnadienesProgesteroneReceptors, Progesteroneulipristal acetateFemale hormonesMED12 mutationSmooth muscle cellsUlipristal acetateUterine leiomyomasXenograft models

Identifiers

PMID41238650
PMCPMC12618505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.